Last fall, new data from TAILORx, the largest ever breast cancer treatment trial, revealed the five-year outcomes of women with the most common type of breast cancer who received a high score on a molecular test that assesses the risk of cancer return. These patients were treated with both hormone therapy and chemotherapy.
The data showed that 93% of the group of women with a Recurrence Score of 26-100 were estimated to be cancer-free at five years, an outcome much better than expected with hormone therapy alone.
The Oncotype DX Breast Recurrence Score® is a tumor test that measures the presence of 21 genes known to cause breast cancer. A score of 26 to 100 (on a 100-point scale) indicates a likelihood of cancer returning: the higher the score the higher the risk.
“This new analysis provides the largest data set on outcomes in patients with early breast cancer and high Recurrence Score results. It confirms the importance of using the test to identify the minority of patients who will receive a significant benefit from adding adjuvant chemotherapy to endocrine therapy,” said lead author Joseph A. Sparano, MD (pictured right) of the Albert Einstein Cancer Center and Montefiore Health System in New York. Dr. Sparano is vice chair of the ECOG-ACRIN Cancer Research Group.
The TAILORx trial answers questions about when to use chemotherapy to treat the most common type of breast cancer: hormone receptor-positive, HER2-negative, axillary lymph node-negative. The original conclusion of the TAILORx trial was that most women with early breast cancer (70%) do not benefit from chemotherapy. The finding was reported in the New England Journal of Medicine in May 2018.
Now, the new data confirms that the test can help identify the small number of patients for whom chemotherapy will provide significant benefit. This data was published in JAMA Oncology and presented at a meeting hosted by the European Society for Medical Oncology.
Learn more about the outcomes of the women in TAILORx who received chemotherapy.